Compare · ERAS vs PMVP
ERAS vs PMVP
Side-by-side comparison of Erasca Inc. (ERAS) and PMV Pharmaceuticals Inc. (PMVP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ERAS and PMVP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ERAS is the larger of the two at $5.88B, about 61.8x PMVP ($95.1M).
- PMVP has been more active in the news (3 items in the past 4 weeks vs 2 for ERAS).
- ERAS has more recent analyst coverage (19 ratings vs 11 for PMVP).
- Company
- Erasca Inc.
- PMV Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $5.88B
- $95.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 2
- 3
- Recent ratings
- 19
- 11
PMV Pharmaceuticals Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Latest ERAS
- Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
- Erasca to Present at Upcoming Conferences in November
- SEC Form 8-K filed by Erasca Inc.
- Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
- Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Erasca Inc. filed SEC Form 8-K: Other Events
- Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
- SEC Form 144 filed by Erasca Inc.
- SEC Form 4 filed by President, R&D Fuchs Charles S.
- SEC Form 3 filed by new insider Fuchs Charles S.
Latest PMVP
- SEC Form 10-Q filed by PMV Pharmaceuticals Inc.
- PMV Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
- SEC Form 4 filed by PMV Pharmaceuticals Inc.
- SEC Form 3 filed by PMV Pharmaceuticals Inc.
- PMV Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
- PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
- PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
- SEC Form 424B3 filed by PMV Pharmaceuticals Inc.